Nicotinamide reduces photodynamic therapy-induced immunosuppression in humans

British Journal of Dermatology

Volumn 167, Issue 3, 2012, Pages 631-636

  Thanos, S M ^a   Halliday, G M ^a   Damian, D L ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID METHYL ESTER; NICOTINAMIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DELAYED HYPERSENSITIVITY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HUMAN EXPERIMENT; IMMUNOSUPPRESSIVE TREATMENT; IRRADIATION; MALE; NORMAL HUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RED LIGHT;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ADULT; AGED; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNE SYSTEM DISEASES; IMMUNE TOLERANCE; MALE; MIDDLE AGED; NIACINAMIDE; PHOTOCHEMOTHERAPY; SEASONS; TABLETS; TUBERCULIN TEST; VITAMIN B COMPLEX;

EID: 84865613041     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2012.11109.x     Document Type: Article

References (31)

1. Morton CA, McKenna KE, Rhodes LE,. Guidelines for topical photodynamic therapy: update. On behalf of the British Association of Dermatologists Therapy Guidelines and Audit Committee and the British Photodermatology Group. Br J Dermatol 2008; 159: 1245-66.
2. Sandberg C, Halldin CB, Ericson MB, et al. Bioavailability of aminolaevulinic acid and methylaminolaevulinate in basal cell carcinomas: a perfusion study using microdialysis in vivo. Br J Dermatol 2008; 159: 1170-6.
3. Frost GA, Halliday GM, Damian DL,. Photodynamic therapy-induced immunosuppression in humans is prevented by reducing the rate of light delivery. J Invest Dermatol 2011; 131: 962-8.
4. Norval M, Halliday GM,. The consequences of UV-induced immunosuppression for human health. Photochem Photobiol 2011; 87: 965-77.
5. Dragieva G, Hafner J, Dummer R, et al. Topical photodynamic therapy in the treatment of actinic keratoses and Bowen's disease in transplant recipients. Transplantation 2004; 77: 115-21. (Pubitemid 38116882)
6. Hayami J, Okamoto H, Sugihara A, et al. Immunosuppressive effects of photodynamic therapy by topical aminolevulinic acid. J Dermatol 2007; 34: 320-7. (Pubitemid 46535953)
7. Mroz P, Hamblin MR,. The immunosuppressive side of PDT. Photochem Photobiol Sci 2011; 10: 751-8.
8. Matthews YJ, Damian DL,. Topical photodynamic therapy is immunosuppressive in humans. Br J Dermatol 2010; 162: 637-41.
9. Evangelou G, Farrar MD, White RD, et al. Topical aminolaevulinic acid-photodynamic therapy produces an inflammatory infiltrate but reduces Langerhans cells in healthy human skin in vivo. Br J Dermatol 2011; 165: 513-19.
10. Evangelou G, Farrar MD, Cotterell L, et al. Topical photodynamic therapy significantly reduces epidermal Langerhans cells during clinical treatment of basal cell carcinoma. Br J Dermatol 2012; 166: 1112-15.
11. Park J, Halliday GM, Surjana D, et al. Nicotinamide prevents ultraviolet radiation-induced cellular energy loss. Photochem Photobiol 2010; 86: 942-8.
12. Gensler HL,. Prevention of photoimmunosuppression and photocarcinogenesis by topical nicotinamide. Nutr Cancer 1997; 29: 157-62. (Pubitemid 28009838)
13. Gensler HL, Williams T, Huang AC, et al. Oral niacin prevents photocarcinogenesis and photoimmunosuppression in mice. Nutr Cancer 1999; 34: 36-41. (Pubitemid 29382913)
14. Damian DL, Patterson CRS, Stapelberg M, et al. Ultraviolet radiation-induced immunosuppression is greater in men and prevented by topical nicotinamide. J Invest Dermatol 2008; 128: 447-54.
15. Yiasemides E, Sivapirabu G, Halliday GM, et al. Oral nicotinamide protects against ultraviolet radiation-induced immunosuppression in humans. Carcinogen 2009; 30: 101-5.
16. Sivapirabu G, Yiasemides E, Halliday GM, et al. Topical nicotinamide modulates cellular energy metabolism and provides broad-spectrum protection against ultraviolet radiation-induced immunosuppression in humans. Br J Dermatol 2009; 161: 1357-64.
17. Surjana D, Halliday GM, Martin AJ, et al. Oral nicotinamide reduces actinic keratoses in phase II double-blinded randomized controlled trials. J Invest Dermatol 2012; 132: 1498-500.
18. Knip M, Douek IF, Moore WP, et al. Safety of high-dose nicotinamide: a review. Diabetologia 2000; 43: 1337-45.
19. Damian DL, Halliday GM,. Measurement of ultraviolet radiation-induced suppression of recall contact and delayed-type hypersensitivity in humans. Methods 2002; 28: 34-45.
20. Bouros D, Zeros G, Panaretos C, et al. Palpation vs. pen method for the measurement of skin tuberculin reaction (Mantoux test). Chest 1991; 99: 416-19.
21. Kuchel JM, Barnetson RS, Halliday GM,. Cyclobutane pyrimidine dimer formation is a molecular trigger for solar-simulated ultraviolet radiation-induced suppression of memory immunity in humans. Photochem Photobiol Sci 2005; 4: 577-82. (Pubitemid 41176272)
22. Wang S, Xing Z, Vosler PS, et al. Cellular NAD replenishment confers marked neuroprotection against ischemic cell death: role of enhanced DNA repair. Stroke 2008; 39: 2587-95.
23. Ericson MB, Sandberg C, Stenquist B, et al. Photodynamic therapy of actinic keratosis at varying fluence rates: assessment of photobleaching, pain and primary clinical outcome. Br J Dermatol 2004; 151: 1204-12. (Pubitemid 40030168)
24. Cottrell WJ, Paquette AD, Keymel KR, et al. Irradiance-dependent photobleaching and pain in d-aminolevulinic acid-photodynamic therapy of superficial basal cell carcinomas. Clin Cancer Res 2008; 14: 4475-83.
25. Langmack K, Mehta R, Twyman P, et al. Topical photodynamic therapy at low fluence rates-theory and practice. J Photochem Photobiol, B 2001; 60: 37-43. (Pubitemid 32401360)
26. Henderson BW, Gollnick SO, Snyder JW, et al. Choice of oxygen-conserving treatment regimen determines the inflammatory response and outcome of photodynamic therapy of tumors. Cancer Res 2004; 64: 2120-6. (Pubitemid 38339462)
27. Jacobson EL, Dame AJ, Pyrek JS, et al. Evaluating the role of niacin in human carcinogenesis. Biochimie 1995; 77: 394-8.
28. De Murcia JM, Niedergang C, Trucco C, et al. Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc Natl Acad Sci USA 1997; 94: 7303-7. (Pubitemid 27345310)
29. Korbelik M, Sun J, Payne PW,. Activation of poly(adenosine diphosphate-ribose) polymerase in mouse tumors treated by photodynamic therapy. Photochem Photobiol 2003; 78: 400-6.
30. Casas A, Di Venosa G, Hasan T, et al. Mechanisms of resistance to photodynamic therapy. Curr Med Chem 2011; 18: 2486-515.
31. Fitzpatrick TB,. The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol 1998; 124: 869-71.